Clinical Trial Update: TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating TC-D101, a DLL3-targeted CAR-T cell therapy, for DLL3-positive small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• TC-D101

Snippet

Sponsor: TCRCure Biopharma Ltd. | Conditions: Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy | EARLY_Phase 1 | Status: RECRUITING